Trial | NCT02168543  Report issue

Title

1% Alendronate Gel in Treatment of Chronic Periodontitis Among Smokers
Clinical Efficacy of Subgingivally Delivered 1% Alendronate in the Treatment of Smokers With Chronic Periodontitis: a Randomized Placebo Controlled Clinical Trial.

  • Phase

    Phase 2

  • Study Type

    Interventional

  • Status

    Completed No Results Posted

  • Study Participants

    46
Locally delivered Alendronate (ALN) have potent inhibitory effect on bone and increases new bone formation in chronic periodontitis patients
Till date no study has reported the effect of local delivery of ALN in chronic periodontitis patients among smokers. Hence the aim of this study is to investigate the clinical and radiographic effects of locally delivered ALN as an adjunct to the non surgical treatment in smoker chronic periodontitis patients.
Study Started
Mar 31
2009
Primary Completion
Jan 31
2011
Study Completion
Apr 30
2011
Last Update
Jun 20
2014
Estimate

Drug Alendronate

Drug Placebo

Alendronate Experimental

1% Alendronate gel once in periodontal pocket (Gums)

Placebo Placebo Comparator

Placebo gel once in periodontal pocket (Gums)

Criteria 

Inclusion Criteria:

Systemically healthy subjects with probing depth (PD) ≥ 5 mm or periodontal attachment level (PAL) ≥ 4 to 6 mm and a radiographical vertical bone loss ≥ 3 mm
No history of periodontal therapy in preceding last 6 months
No use of antibiotics in the preceding 6 months

Exclusion Criteria:

Subjects with known systemic disease
Known or suspected allergy to the ALN/bisphosphonate group
Those on systemic ALN/bisphosphonate therapy
Subjects with aggressive periodontitis,
Use of smokeless tobacco in any form,
Alcoholics
Immunocompromised subjects
Pregnant or lactating females
No Results Posted